Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients

British Journal of Haematology

Volumn 166, Issue 2, 2014, Pages 306-308

  Monjanel, Hélène ^a   Deville, Laure ^a   Ram Wolff, Caroline ^a   Venon, Marie Dominique ^a   Franchi, Patricia ^a   Benet, Claire ^a   de Kerviler, Eric ^a   Malphettes, Marion ^a   Thieblemont, Catherine ^a   Brice, Pauline ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Anaplastic large cell lymphoma; Brentuximab vedotin; Hodgkin lymphoma; Monoclonal antibody; Primary refractory

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISOLONE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; HODGKIN DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LETTER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ANAPLASTIC LARGE-CELL LYMPHOMA; BRENTUXIMAB VEDOTIN; HODGKIN LYMPHOMA; MONOCLONAL ANTIBODY; PRIMARY REFRACTORY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903748434     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12849     Document Type: Letter

References (6)

1. Brice, P. (2008) Managing relapsed and refractory Hodgkin lymphoma. British Journal of Haematology, 141, 3-13.
2. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
3. Gascoyne, R.D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B.F., Greiner, T.C., Morris, S.W., Connors, J.M., Vose, J.M., Viswanatha, D.S., Coldman, A. & Weisenburger, D.D. (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood, 93, 3913-3921.
4. Pro, B., Advani, R., Brice, P., Bartlett, N.L., Rosenblatt, J.D., Illidge, T., Matous, J., Ranchandren, R., Fanale, M., Connors, J.M., Yang, Y., Sievers, E.L., Kennedy, D.A. & Shustov, A. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Journal of Clinical Oncology, 30, 2190-2196.
5. Rothe, A., Sasse, S., Goergen, H., Eichenauer, D.A., Lohri, A., Jäger, U., Bangard, C., Böll, B., von Bergwelt Baildon, M., Theurich, S., Borchmann, P. & Engert, A. (2012) Brentuximab vedotin for relapsed or refractory CD30 + hematologic malignancies: the German Hodgkin Study Group experience. Blood, 120, 1470-1472.
6. Younes, A., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Savage, K.J., Ramchandren, R., Bartlett, N.L., Cheson, B.D., de Vos, S., Forero-Torres, A., Moskowitz, C.H., Connors, J.M., Engert, A., Larsen, E.K., Kennedy, D.A., Sievers, E.L. & Chen, R. (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. Journal of Clinical Oncology, 30, 2183-2189.